Gw, You do not have any prove that Allergan has ever taken an eye product and move it from $0 to $100M in three years, is that balance?...NO! if you have the prove please, provide it, not just mentioned the "plausibility".
Look at Pharmos, they have a very easy eye product to become popular, two drugs with clearcut side effects advantages, Lotemax and Alrex. They have BOL, as big as one could get in eye care including the very important surgical aspect of the business, and where is the product after almost 4 years post FDA approval, and 2 of marketing? $3M of revenue for pharmos (not even $15M total gross for BOL). Allergan itself is the competition.
Look at CCSI and SPRX, nice devices, both with good partners, the bilirubin meters are just reaching $1.5M gross BOTH companies income! with very similar prices.
Look at Ligand in the oncology/aids/dermatology niche market, 4 products and not $10M in sales after one year plus!
A very specialized market is MORE difficult to reach, not easier, and the market is limited on its own.
Do you think people is losing eyes right and left after surgical procedures? NO!, there is a need, but not huge, and not easy to reach. It ain't lipitor/viagra you are talking about! |
